论文部分内容阅读
[目的]观察痰瘀同治方联合化疗治疗进展期胃癌术后患者的临床疗效。[方法]将符合纳入标准的进展期胃癌术后患者,随机分为治疗组和对照组各30例。对照组单纯化疗,具体为:奥沙利铂注射液130mg/m2,第1天静脉滴注,同时口服替吉奥胶囊80mg/m2,第1天至第14天,21天为1个周期,共6个周期。随后单独口服替吉奥6个周期。治疗组在化疗的基础上联合痰瘀同治方为主的辨病辨证相结合中医治疗,每日1剂,连续服用2年。比较2者术后半年、1年、2年的复发转移率,无进展生存时间(PFS),及治疗前后中医证候评分、生活质量评分(Karnofsky),及化疗毒副反应发生情况。[结果]治疗组半年、1年、2年复发转移率分别为:6.67%、20%、30%,对照组分别为:6.67%、33.33%、56.67%,治疗组2年复发转移率低于对照组,差异有统计学意义(P<0.05)。治疗组的无进展生存时间(PFS)为28.1个月,对照组为21.1个月,2组比较差异有统计学意义(P<0.05)。治疗组中医证候评分和生活质量评分改善程度均优于对照组(P<0.05)。毒副反应中治疗组恶心呕吐反应较对照组轻,2组比较差异有统计学意义(P<0.05)。[结论]痰瘀同治方联合化疗能降低进展期胃癌术后患者的复发转移率,延长无进展生存时间,改善患者中医证候和生活质量,降低化疗毒副反应。
[Objective] To observe the clinical efficacy of Phlegm and blood stasis combined with chemotherapy in patients with advanced gastric cancer after operation. [Methods] The patients with advanced gastric cancer who met the inclusion criteria were randomly divided into treatment group (n = 30) and control group (n = 30). The control group chemotherapy alone, specifically: oxaliplatin injection 130mg / m2, intravenous drip on the first day, while oral tigegio capsules 80mg / m2, the first day to the fourteenth day, 21 days for a cycle, A total of 6 cycles. Afterwards, Tigio alone was orally administered for 6 cycles. Treatment group on the basis of chemotherapy combined with phlegm and blood stasis-based syndrome differentiation combined with traditional Chinese medicine treatment, a daily dose of 2 consecutive years. The recurrence and metastasis rates, progression-free survival time (PFS), TCM syndrome scores before and after treatment, Karnofsky score, and the incidence of chemotherapy side effects were compared between the two groups at six months, one year and two years after operation. [Results] The recurrence and metastasis rates in the treatment group at 6 months, 1 year and 2 years were 6.67%, 20% and 30% respectively. The control groups were 6.67%, 33.33% and 56.67% Control group, the difference was statistically significant (P <0.05). The progression-free survival time (PFS) was 28.1 months in the treatment group and 21.1 months in the control group, with significant difference between the two groups (P <0.05). The scores of TCM syndrome and quality of life in the treatment group were better than those in the control group (P <0.05). The side effects of nausea and vomiting in treatment group were less than those in control group. The differences between the two groups were statistically significant (P <0.05). [Conclusion] Phlegm and blood stasis combined with chemotherapy can reduce the recurrence and metastasis rate, prolong the progression-free survival time, improve TCM syndromes and quality of life in patients with advanced gastric cancer, and reduce the side effects of chemotherapy.